Imfinzi is an intravenous programmed death ligand-1 checkpoint inhibitor for the treatment of locally advanced or metastatic urothelial cancer in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. The interaction between the programmed death-1 (PD-1) receptor and its ligands is a key immune checkpoint pathway hijacked by certain tumors to suppress immune system rejection. This pathway is therefore a promising target for new immunotherapies. It is proposed that blocking PD-1 interaction with its ligands makes tumor cells vulnerable to attack from immune cells.Imfinzi is in development for several other oncology indications.
If you have a Hayes login, click here to view the full report on the Knowledge Center.